Vitroscope has successfully raised USD 5 million in a seed round led by Cerberus Ventures and YZR Capital. The Trondheim-based biotech company aims to commercialize its laboratory platform designed for keeping human tissue viable for longer periods. The seed funding brings the total capital raised, including $2 million from the Norwegian Research Council, to $8.8 million.
This round saw participation from Arcas Ventures, Golden Egg Check, and Devico Invest, along with various angel investors, including Carles Reina, Fàtima Godall, and Oskari Pétas. This infusion of capital will be directed towards commercializing the vitro.alive bench platform and validating its high-capacity version, vitro.scale. Vitroscope's technology tackles issues with traditional cell culture methods that limit the longevity of living tissue samples.
The company intends to start customer testing of vitro.scale in 2027, followed by a product launch the following year. This advancement could greatly enhance the capability of researchers to conduct experiments on living tissue under more realistic conditions.
